Miura Kazutoyo, Deng Bingbing, Wu Yimin, Zhou Luwen, Pham Thao P, Diouf Ababacar, Wu Chia-Kuei, Lee Shwu-Maan, Plieskatt Jordan L, Morin Merribeth J, Long Carole A
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Vaccine. 2019 Apr 3;37(15):2073-2078. doi: 10.1016/j.vaccine.2019.02.071. Epub 2019 Mar 5.
The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM, or a mixture of unconjugated Pfs230 and CRM proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 IgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development.
标准膜饲试验(SMFA)是一种功能性试验,已被用于指导针对恶性疟原虫疟疾的传播阻断疫苗(TBV)的研发。对于作为TBV研发主要靶抗原的Pfs230,一些研究曾对单一抗Pfs230多克隆或单克隆抗体(每项研究一种抗体)进行系列稀释测试,并显示出剂量依赖性反应。此外,有报道称,在补体存在的情况下,抗Pfs230多克隆和单克隆抗体的SMFA活性会增强。然而,尚未对多个样本进行分析,且未通过SMFA共同评估抗Pfs230抗体滴度、IgG亚类谱和亲和力对传播减少活性(TRA)的影响。在本报告中,通过酶联免疫吸附测定(ELISA)评估了来自五项不同小鼠免疫研究的总共39种独特抗Pfs230 IgG的酶联免疫吸附测定单位(EU)、IgG2/IgG1比率和亲和力,并通过SMFA评估了其功能(传播减少活性百分比,%TRA)。使用氢氧化铝或Montanide ISA720佐剂,用单独的Pfs230、与CRM偶联的Pfs230或未偶联的Pfs230和CRM蛋白的混合物对小鼠进行免疫。在所有研究中,Pfs230抗原均来自同一来源。抗Pfs230 IgG的EU与%TRA之间存在显著相关性(Spearman秩检验,p < 0.0001)。值得注意的是,多元线性回归分析表明,在调整EU后,IgG2/IgG1比率和亲和力均显著影响%TRA(p = 0.003至p = 0.014,取决于模型)。结果表明,除了抗体滴度外,还应分别评估IgG2/IgG1比率和亲和力,以预测抗Pfs230抗体对未来疫苗研发的生物学活性。